Skip to main content
. 2020 Sep 11;126(22):4867–4877. doi: 10.1002/cncr.33142

Figure 2.

Figure 2

Kaplan‐Meier estimates of OS among patients with no PD‐L1 expression (TPS < 1%): (A) OS for patients who received pembrolizumab plus chemotherapy versus chemotherapy alone and (B) subgroup analysis of OS. ECOG indicates Eastern Cooperative Oncology Group; OS, overall survival; PD‐L1, programmed death ligand 1; TPS, tumor proportion score.